BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30714446)

  • 1. PET-derived tumor metrics predict DLBCL response and progression-free survival.
    Islam P; Goldstein J; Flowers CR
    Leuk Lymphoma; 2019 Aug; 60(8):1965-1971. PubMed ID: 30714446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
    J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma.
    Song MK; Chung JS; Shin HJ; Moon JH; Lee JO; Lee HS; Lee SM; Lee GW; Lee SE; Kim SJ
    Cancer Sci; 2012 Mar; 103(3):477-82. PubMed ID: 22126515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
    Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G
    Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
    Pregno P; Chiappella A; Bellò M; Botto B; Ferrero S; Franceschetti S; Giunta F; Ladetto M; Limerutti G; Menga M; Nicolosi M; Priolo G; Puccini B; Rigacci L; Salvi F; Vaggelli L; Passera R; Bisi G; Vitolo U
    Blood; 2012 Mar; 119(9):2066-73. PubMed ID: 22234681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.
    Song MK; Chung JS; Shin HJ; Lee SM; Lee SE; Lee HS; Lee GW; Kim SJ; Lee SM; Chung DS
    Ann Hematol; 2012 May; 91(5):697-703. PubMed ID: 22071570
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
    Gupta N; Singh N
    Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.